LAMP Assay Validated for MRSA in Invasive Samples
By LabMedica International staff writers Posted on 16 Jun 2017 |
Image: The eazyplex MRSA test system is designed for the detection of S. aureus and MRSA (pictured) in invasive samples such as pleural and synovial fluid (Photo courtesy of MNT).
Staphylococcus aureus is a leading cause of bone and joint infections and one of the most common causative pathogens of bacterial pneumonia in children. An increased risk of mortality from invasive staphylococcal infections has been attributed to methicillin-resistant S. aureus (MRSA).
The detection of pathogens by loop-mediated isothermal amplification (LAMP), which is a rapid, cost-effective, and simple method with high sensitivity, has resolved the major limitations of time-consuming culture-based methods and costly polymerase chain reaction (PCR) molecular techniques.
Molecular microbiologists at the University Hospital of Sant Joan de Déu (Barcelona, Spain) evaluated the analytical and diagnostic performance of the eazyplex MRSA test system for the detection of S. aureus and MRSA in invasive samples such as pleural and synovial fluid, in comparison to the gold standard bacterial culture. A volume of spiked pleural sample (analytical validation) or pleural/synovial fluid (diagnostic validation) was diluted in sterile water and genomic DNA was extracted using the NucliSENS EasyMag system.
The team pipetted 25 mL of a DNA mixture were into the six wells of the eazyplex MRSA strip. This contains a reagent mix and six primers in each cap for the simultaneous but individual amplification of Staphylococcus epidermidis- and S. aureus-specific genes, as well as resistance genes mecA and mecC for the detection of MRSA. Amplification products were generated by isothermal autocycling DNA synthesis and visualized by real-time fluorescence measurement with the Genie II device.
The new system appropriately detected a quality control panel of clinical samples with DNA of methicillin-sensitive S. aureus (MSSA), MRSA, and other pathogens. The limit of detection (LoD) was established at 6.4 × 103 CFU/mL for S. aureus and 1.0 × 104 CFU/mL for MRSA. Diagnostic validation of the eazyplex MRSA assay was performed on 51 prospective clinical invasive samples, resulting in sensitivity and specificity values of 83.3% and 97.8%, respectively, for S. aureus detection. The mean turnaround time was 70 minutes.
The authors concluded that the eazyplex MRSA test system was found to have promising potential as a diagnostic tool for the early detection of S. aureus in samples collected from normally sterile body sites. The study was published on in the June 2017 issue of the International Journal of Infectious Diseases.
Related Links:
University Hospital of Sant Joan de Déu
The detection of pathogens by loop-mediated isothermal amplification (LAMP), which is a rapid, cost-effective, and simple method with high sensitivity, has resolved the major limitations of time-consuming culture-based methods and costly polymerase chain reaction (PCR) molecular techniques.
Molecular microbiologists at the University Hospital of Sant Joan de Déu (Barcelona, Spain) evaluated the analytical and diagnostic performance of the eazyplex MRSA test system for the detection of S. aureus and MRSA in invasive samples such as pleural and synovial fluid, in comparison to the gold standard bacterial culture. A volume of spiked pleural sample (analytical validation) or pleural/synovial fluid (diagnostic validation) was diluted in sterile water and genomic DNA was extracted using the NucliSENS EasyMag system.
The team pipetted 25 mL of a DNA mixture were into the six wells of the eazyplex MRSA strip. This contains a reagent mix and six primers in each cap for the simultaneous but individual amplification of Staphylococcus epidermidis- and S. aureus-specific genes, as well as resistance genes mecA and mecC for the detection of MRSA. Amplification products were generated by isothermal autocycling DNA synthesis and visualized by real-time fluorescence measurement with the Genie II device.
The new system appropriately detected a quality control panel of clinical samples with DNA of methicillin-sensitive S. aureus (MSSA), MRSA, and other pathogens. The limit of detection (LoD) was established at 6.4 × 103 CFU/mL for S. aureus and 1.0 × 104 CFU/mL for MRSA. Diagnostic validation of the eazyplex MRSA assay was performed on 51 prospective clinical invasive samples, resulting in sensitivity and specificity values of 83.3% and 97.8%, respectively, for S. aureus detection. The mean turnaround time was 70 minutes.
The authors concluded that the eazyplex MRSA test system was found to have promising potential as a diagnostic tool for the early detection of S. aureus in samples collected from normally sterile body sites. The study was published on in the June 2017 issue of the International Journal of Infectious Diseases.
Related Links:
University Hospital of Sant Joan de Déu
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans